2026-03-08T16:39:13Z https://asahikawa-med.repo.nii.ac.jp/oai

oai:asahikawa-med.repo.nii.ac.jp:00006010 2023-06-19T12:05:10Z 7 7:24

Role of the cannabinoid signaling in the brain orexin- and ghrelin-induced visceral antinociception in conscious rats 奥村, 利勝 オクムラ, トシカツ 野津, 司 ノヅ, ツカサ 粂井, 志麻 クメイ, シマ 大平, 賀子 オオヒラ, マスミ Cannabinoid Neuropeptide Visceral sensation PMID：29958814 We hypothesized that the cannabinoid (CB) system may mediate the brain orexin- or ghrelin-induced visceral antinociception. Intraperitoneal injection of either CB1/2 agonist, WIN 55212 or O-Arachidonoyl ethanolamine increased the threshold volume of colonic distension-induced abdominal withdrawal reflex in rats, suggesting CB could induce visceral antinociception. Pretreatment with either the CB1 or CB2 antagonist potently blocked the centrally injected orexin-A-induced antinociceptive action against colonic distension while CB2 but not CB1 antagonist blocked the brain ghrelin-induced visceral antinociception. These results suggest that the cannabinoid signaling may be involved in the central orexin- or ghrelin-induced antinociceptive action in a different mechanistic manner. This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/ licenses/by-nc-nd/4.0/) text application/pdf 2018-06-01 eng journal article VoR https://asahikawa-med.repo.nii.ac.jp/records/6010 10.1016/j.jphs.2018.06.001. 1347-8613 Journal of Pharmacological Sciences 137 2 230 232 https://asahikawa-med.repo.nii.ac.jp/record/6010/files/7139.pdf application/pdf 467.8 kB 2021-07-06